Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate

BEVERLY, MA – January 2, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, reported today that the U.S. Patent & Trademark Office recently announced the awarding of a new patent allocated to Brilacidin.

Brilacidin, the Company’s defensin-mimetic drug candidate, has been successfully evaluated in clinical trials in oral mucositis, inflammatory bowel disease and serious skin infections, with planned extension into dermatological diseases.

The “Issue Notification” of the patent (Projected U.S. Patent Number 10166232) covers Brilacidin in the form of a pharmaceutical composition containing water. The pharmaceutical composition can also contain Tris-buffered saline. The patent covers Brilacidin in combination with additional medicaments, such as: an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent and an anti-hypertensive agent.

The new patent builds on the “Notice of Allowance” directed to Brilacidin, including oral, buccal, and sublingual pharmaceutical compositions of Brilacidin.

“As Brilacidin continues to show compelling therapeutic benefits across multiple indications, the Company is taking the necessary steps to broaden the asset’s intellectual property estate,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Brilacidin is a unique drug candidate with the potential to be useful in numerous clinical indications alone or in combination with other medications or agents. This important new patent helps ensure we are positioning the Brilacidin franchise for future successes as we plan to advance Brilacidin into additional clinical trials, including pivotal studies for oral mucositis in 2019, with the end goal of commercialization.”